| 产品名称： | Bacillus subtilis (Ehrenberg) Cohn |
|---|---|
| 商品货号： | TS154448 |
| Strain Designations： | MB 4974 |
| Application： | Produces avermectin avermectins |
| Biosafety Level： | 1
Biosafety classification is based on U.S. Public Health Service Guidelines, it is the responsibility of the customer to ensure that their facilities comply with biosafety regulations for their own country. |
| Product Format： | freeze-dried |
| Disclosure： | This material is cited in a US or other Patent and may not be used to infringe the claims. Depending on the wishes of the Depositor, ATCC may be required to inform the Patent Depositor of the party to which the material was furnished. This material may not have been produced or characterized by ATCC. |
| Preceptrol®： | no |
| Type Strain： | no |
| Comments： | Glycosylation of immunomycin and FK506 |
| Medium： | ATCC® Medium 3: Nutrient agar or nutrient broth |
| Growth Conditions： | Temperature: 30.0°C |
| Name of Depositor： | Merck & Co., Inc. |
| U.S. Patent Number： | |
| References： | Petuch BR, et al. Novel avermectins are produced from known microorganisms. US Patent 5,070,015 dated Dec 3 1991 Petuch BR, et al. Microbial transformation of immunosuppressive compounds. III. Glucosylation of immunomycin (FR 900520) and FK 506 by Bacillus subtilis TS154448. J. Ind. Microbiol. 13: 131-135, 1994. PubMed: 7513528 |
产品中心 Product Center
联系我们CONTACT US
-
0574-87917803
24小时服务热线 -
testobio@163.com
销售邮箱 -
浙江省宁波市高新区晶辉路866弄33号智造港E4幢3楼
地址
联系方式
-
章丽敏
17757489010 -
朱静
18067106081 -
李晴
18067408036 -
李晶晶
13375187189 -
周雪
13372109301
| 产品名称： | Bacillus subtilis (Ehrenberg) Cohn |
|---|---|
| 商品货号： | TS154448 |
| Strain Designations： | MB 4974 |
| Application： | Produces avermectin avermectins |
| Biosafety Level： | 1
Biosafety classification is based on U.S. Public Health Service Guidelines, it is the responsibility of the customer to ensure that their facilities comply with biosafety regulations for their own country. |
| Product Format： | freeze-dried |
| Disclosure： | This material is cited in a US or other Patent and may not be used to infringe the claims. Depending on the wishes of the Depositor, ATCC may be required to inform the Patent Depositor of the party to which the material was furnished. This material may not have been produced or characterized by ATCC. |
| Preceptrol®： | no |
| Type Strain： | no |
| Comments： | Glycosylation of immunomycin and FK506 |
| Medium： | ATCC® Medium 3: Nutrient agar or nutrient broth |
| Growth Conditions： | Temperature: 30.0°C |
| Name of Depositor： | Merck & Co., Inc. |
| U.S. Patent Number： | |
| References： | Petuch BR, et al. Novel avermectins are produced from known microorganisms. US Patent 5,070,015 dated Dec 3 1991 Petuch BR, et al. Microbial transformation of immunosuppressive compounds. III. Glucosylation of immunomycin (FR 900520) and FK 506 by Bacillus subtilis TS154448. J. Ind. Microbiol. 13: 131-135, 1994. PubMed: 7513528 |
